Dosage ; 25-50mg BD (max. 100mg daily).
Slow IV: 5-10mg over 10 minutes. May be repeated after 20-30 minutes.
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Apresoline | Novartis Pharma | C.Mehta & Co Ltd. | 25mg | 100 | Tablet | per tablet | KES 1,120 |
| Apresoline | Novartis Pharma | C.Mehta & Co Ltd. | 20mg | 5 | Injection | per ml | KES 996 |
| Hydralazine | Cosmos Limited. | Cosmos Limited | 25mg | 100 | Tablet | per tablet | KES 400.00 |
| Hydralazine | Cosmos Limited. | Cosmos Limited | 25mg | 56 | Tablet | per tablet | KES 280 |
| Hydralazine | Cosmos Limited. | Cosmos Limited | 25mg | 500 | Tablet | per tablet | KES 1,115 |
| Hydralazine | Remedica Ltd. | Twokay Chemicals Ltd | 25mg | 1000 | Tablet | per tablet | KES 3,600.00 |
| Hydralazine More info | |
|---|---|
| Mode Of Action | Direct relaxation of vascular smooth muscle resulting peripheral vasodilating effect e.g. hydralazine |
| Drug Indication | Essential hypertension, CHF, severe aortic insufficiency and after valve replacement. |
| Precautions | Renal or / and hepatic impairment, hypotension, tachycardia, pregnancy and lactation, coronary heart disease, CCF. |
| Contra-Indications | Severe tachycardia, cor pulmonale, dissecting aortic aneurysm, idiopathic systemic lupus erythematosus, high output heart failure, mitral valvular rheumatic heart disease, and hypersensitivity to hydralazine. |
| Side Effects | Headache, anorexia, fluid retention, postural hypotension, nasal congestion, nausea and vomiting, diarrhoea, palpitations, tachycardia, angina pectoris, toxic reactions, SLE syndrome, blood dyscrasia, urinary retention, weight loss, myalgia, flushing. |
| Dosage | 25-50mg BD (max. 100mg daily). Slow IV: 5-10mg over 10 minutes. May be repeated after 20-30 minutes. |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |
| Drug Sub-Category | Vasodilator antihypertensives |